Evaluating the causal relationships between urate, blood pressure, and kidney function in the general population: a two-sample Mendelian Randomization study

Haotian Tang, MRes *, Venexia M Walker, PhD *, Tom R Gaunt, PhD *

April 24, 2024

Corresponding Author:

Prof. Tom R Gaunt

Medical Research Council Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom.

Email: Tom.Gaunt@bristol.ac.uk

*Medical Research Council Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Associations between blood urate levels, blood pressure (BP), and kidney function have previously been reported in observational studies. However, causal inference between these three traits is challenging due to potentially bidirectional relationships. We applied bidirectional univariable Mendelian randomization (UVMR) to assess the causal relationships between urate levels, BP, and kidney function, proxied by estimated glomerular filtration rate (eGFR), by using genetic associations from both UK Biobank and CKDGen. We performed multivariable MR (MVMR) to assess the independent effects of urate and BP on eGFR. Effect estimates are presented as standard deviation (SD) change in outcome per SD increase in exposure [95% confidence interval]. UVMR analysis suggested a bidirectional causal effect between urate and eGFR (urate on log(eGFR): beta=-0.10 [-0.22 to 0.02]; log(eGFR) on urate: beta=-0.11 [-0.17 to -0.04]). There was strong evidence of bidirectional causal effects between urate and SBP (urate on SBP: beta=0.08 [0.04 to 0.11]; SBP on urate: beta=0.13 [0.08 to 0.18]). Similar bidirectional causal effects were identified between urate and DBP (urate on DBP: beta=0.09 [0.05 to 0.14]; DBP on urate: beta=0.13 [0.08 to 0.18]). However, there was weak evidence of a causal effect between BP and eGFR. MVMR results suggested the causal effect of urate on eGFR was independent of BP. Our results provide evidence for bidirectional causal effects between urate and both eGFR and BP, suggesting urate control as a potential intervention to reduce BP and decline in kidney function in the general population, but little evidence of a causal relationship between BP and eGFR.

Introduction

Hyperuricemia, defined as an elevated urate level in the serum, is a common disorder affecting about 20.1% of people in the United States.\(^1\) Hyperuricemia is associated with several different disorders, including gout, hypertension, and chronic kidney disease (CKD).\(^2\) CKD is an irre-
versible and progressive disease, which can lead to end-stage renal disease requiring expensive treatments, such as dialysis or kidney transplantation. Elevated urate levels have been associated with a substantial positive risk of CKD in numerous epidemiological studies, and are a potential risk factor for the development and progression of renal disease in the general population. However, urate, as the byproduct of purine metabolism, is primarily excreted via the kidneys. The natural relationship between urate and kidney function makes it difficult to identify whether the association between urate and CKD is causal, and if so, in which direction.

It has also been reported that higher urate levels are associated with an elevated risk of hypertension. Primary hypertension patients commonly have hyperuricemia, which is more prevalent in patients with accelerated hypertension. Hypertension and CKD are interlinked and represent huge global public health burdens, affecting around 31% and 10% of adults respectively. Renal function deteriorates with sustained hypertension, and blood pressure (BP) regulation deteriorates with progressive renal function loss. Furthermore, the mouse uricase-knockout model has indicated higher urate levels affect the progression of hypertension and reduce kidney function. Understanding the causal relationships between serum urate, BP, and kidney function might help reveal the underlying pathophysiological mechanisms and provide new evidence for clinical and lifestyle intervention.

Utilizing genetic variants as instrumental variables for exposure, Mendelian randomization (MR) can address some of the limitations of observational research including confounding and reserve causation, to evaluate causal inference. MR method relies upon the principle that alleles randomly segregate from parents to offspring, according to Mendel’s Laws of Inheritance. Consequently, it is unlikely that offspring genotypes will be linked to population confounders, such as behavioral and environmental factors. Furthermore, issues with reverse causation are avoided because germline genetic variants are established at conception and temporally precede the risk factors.
being researched. \(^{15,16}\)

Our project aims were to assess the causal relationship between urate, BP, and kidney function in the general population by conducting bidirectional univariable MR (UVMR) and multivariable MR (MVMR) analyses. Kidney function was proxied by estimated glomerular filtration rate (eGFR; derived using serum creatinine). In addition, to examine how the effect of urate on hypertension differs during the life course, we assessed the effects of urate on early-, late-onset, and overall hypertension.

**Methods and materials**

**Study design and data source**

We conducted genome-wide association studies (GWAS) in UK Biobank (UKB) (UKB project 15825), to obtain the summary level data for urate, both systolic and diastolic BP (SBP and DBP), and early-onset, late-onset, and overall hypertension.\(^{17}\) We also obtained the summary statistics of both urate\(^{18}\) and eGFR\(^{19,20}\) from the GWAS of European-ancestry participants carried out by the Chronic Kidney Disease Genetics Consortium (the CKDGen Consortium). We differentiate between the urate datasets from CKDGen and UKB GWAS by labeling them as "Urate (CKD-Gen)"\(^{18}\) and "Urate (UKB)", and distinguish between the two eGFR datasets from CKDGen as "eGFR (CKDGen2016)"\(^{20}\) and "eGFR (CKDGen2019)"\(^{19}\).

To validate the results of our GWAS for the continuous traits urate and BP, we examined their known causal effects on gout and stroke respectively as positive controls using UVMR. We then performed pairwise bidirectional UVMR analyses to evaluate the relationship between urate, BP, and eGFR in general European population samples. Next, we investigated the causal effects of urate on early-onset, late-onset, and overall hypertension by using UVMR. Finally, we used...
MVMR to investigate the causal effects of urate and BP, independent of each other, on eGFR. All MR analyses conducted in this study are shown in Table 1 and the details of GWAS data used for MR analyses are in Table 2 (for positive control results, see Supplementary Materials). Our analysis code is available on GitHub (https://github.com/Haotian2020/Urate_Project2024).

GWAS in UKB

UKB, a large population-based cohort, recruited over 500,000 individuals and collected extensive phenotypic and genotypic data.17 We used the UKB GWAS pipeline, which has been developed by the Medical Research Council (MRC) Integrative Epidemiology Unit (IEU), to perform our GWAS.21 We applied the linear mixed modeling approach, BOLT-LMM, to account for population stratification and relatedness. The covariates in the model included genotyping chip, sex, and age. We conducted urate, SBP, and DBP GWAS using the full UKB sample. For each continuous trait, data were cleaned by removing extreme values, defined as values more than four standard deviations (SDs) from the mean. The urate GWAS with the UKB full sample was used as a sensitivity analysis to avoid sample overlap as both urate18 and eGFR19 were from CKDGen, as sample overlap can cause bias in inverse-variance weighted (IVW) MR estimates.22 Next, we conducted early-onset, late-onset, and overall hypertension GWAS. Hypertension was defined as participants with ICD10 codes I10 and I15 (primary and secondary hypertension respectively). The GWAS of early- and late-onset hypertension are described in section Early- and late-onset hypertension. Finally, we randomly divided the participants with urate data into two halves. For both subsets, we conducted urate, SBP, and DBP GWAS. This split-sample approach provided GWAS results in independent samples to address sample overlap concerns in the MVMR analyses.
Instrument Selection

We selected instruments robustly associated with each phenotype at genome-wide significance ($p < 5\times10^{-8}$). Next, we used `ieugwasr` R package to perform linkage disequilibrium clumping with a window of 10,000kb and a maximum $r^2$ threshold of 0.001 to select independent variants.\cite{23} We calculated F-statistics, which are derived from the variance explained by instruments and the exposure sample size, to evaluate the strength of the genetic instruments for each UVMR analysis\cite{24,25} by using `TwoSampleMR` R package.\cite{26} F-statistics are typically interpreted using an arbitrary threshold of 10 as an indicator for a strong instrument.

Main analyses

UVMR

To estimate the causal effects between urate, BP, and eGFR, we systematically conducted pairwise bidirectional two-sample MR analyses using the IVW method. Both urate and eGFR GWAS summary statistics were downloaded from the CKDGen consortium (http://ckdgen.imbi.uni-freiburg.de/).\cite{19} GWAS summary statistics for SBP and DBP were obtained by conducting novel GWAS in UKB.\cite{17} All GWAS details and UVMR can be found in Table 2 and Table 1. All analyses are presented on the SD scale (see Supplementary Materials).

Early- and late-onset hypertension

We examined the causal effects of urate on early-onset, late-onset, and overall hypertension using UVMR. In the literature, the definition of early-onset hypertension varies from $\leq 35$ to $\leq 55$ years of age.\cite{27,32} Given the UK National Institute for Health and Care Excellence (NICE) makes treatment recommendations based on whether patients are above or below 55 years old,\cite{33} we defined the threshold for early-onset and late-onset hypertension as 55 years old. To reduce misclassifica-
tion, we set a 5-year window before and after the threshold of 55 years old. Therefore, early-onset hypertension was defined as a diagnosis at an age of \( \leq 50 \) years; late-onset hypertension was defined as a diagnosis at an age of \( > 60 \) years. To implement the threshold, the year and month of birth of participants, as well as the date that the ICD10 codes I10 and I15 were first reported, were extracted from UKB. We then randomly assigned a day of birth within the birth month to each participant and calculated the approximate age at which participants were diagnosed with hypertension.

**MVMR**

To investigate whether the effects of urate on eGFR are independent of BP, we applied MVMR using summary level urate genetic associations\(^{18}\) from CKDGen and BP genetic associations from UKB as exposure, with eGFR\(^{19}\) from CKDGen as the outcome. Genetic instruments in MVMR still need to adhere to the instrumental variable assumptions and must be related to at least one exposure. MVMR allows for the inclusion of multiple exposures and separates the direct causal effects of each exposure in the model\(^{34}\). To determine whether the genetic instruments effectively predict each exposure while considering the presence of the other exposure within the MVMR model, we calculated the conditional F-statistic for each exposure\(^{35}\). A conditional F-statistic larger than the arbitrary threshold of 10 indicates that the genetic instruments for MVMR are likely to be strong.

**Sensitivity analyses**

**Sensitivity analyses for UVMR**

By assuming that all exposure SNPs are valid instrumental variables, the IVW method combines the effects of all these SNPs to obtain an overall weighted effect\(^{36}\). However, the validity of MR estimates depends on three assumptions (Figure S1). To evaluate the robustness of our findings\(^{13}\).
we performed different sensitivity analyses, including MR-Egger,\(^\text{37}\) weighted median,\(^\text{38}\) weighted mode, simple mode\(^\text{39}\) and Steiger filtering.\(^\text{40}\) When balanced pleiotropic effects are present, the MR-Egger method exhibits resilience by permitting the intercept in the regression of the SNP-outcome association against the SNP-exposure association to be non-zero. The intercept term in the MR-Egger result can be used as an assessment of directional pleiotropy, with the intercept term being interpreted as a measure of the directional pleiotropy present (pleiotropy tests).\(^\text{37}\) MR-Egger makes the ‘NO Measurement Error’ (NOME) assumption.\(^\text{41, 42}\) We calculated the $I_{GX^2}$ statistics to assess any violation of the NOME assumption. When taken as an estimate of the attenuation bias, an $I_{GX^2}$ statistic higher than 90% corresponds to less than 10% relative bias towards the null.\(^\text{41}\) The weighted median method can provide reliable results even when a maximum of 50% of the instruments are not valid.\(^\text{38}\) The mode method assumes that instruments from the largest subset are valid and identify the same true causal effect.\(^\text{39}\) Finally, we applied Steiger filtering to ensure that each genetic instrument had a stronger association with the exposure than with the outcome, which minimized the risk of reverse causation in bidirectional MR.\(^\text{40}\)

We applied Cochran’s Q-test to assess heterogeneity in each MR analysis by examining the variability in the causal effects of each genetic instrument. When Q significantly exceeds its degrees of freedom (which is calculated as the number of SNPs minus 1), it indicates the presence of heterogeneity.\(^\text{43, 44}\)

To address the sample overlap issue that both the urate and eGFR GWAS from CKDGen used many of the same individuals, we performed a urate GWAS using UKB data and repeated our UVMR analyses to assess the causal relationship between urate and eGFR in non-overlapping samples.

Additionally, to assess the reliability of the instruments for urate, SBP, and DBP, we performed three positive control MR analyses. These were urate on gout, SBP on stroke, and DBP on stroke.
(see Supplementary Materials).

**Sensitivity analyses for eGFR GWAS**

Multiple eGFR GWAS datasets are available from CKDGen\(^{19,20,45}\). To confirm the causal relationship between BP and eGFR as well as address the sample overlap problem in MR analyses, we used eGFR GWAS\(^{20}\) (OpenGWAS\(^{46}\) ID: ieu-a-1105) for sensitivity analyses between eGFR and BP. Additionally, we used BP instruments to compare their SNP effect on \( \log(eGFR) \) from two eGFR GWAS\(^{19,20}\) (see Supplementary Method).

**Sensitivity analyses for MVMR**

Due to the sample overlap problem in which urate\(^{18}\) and eGFR\(^{19}\) GWAS were both from CKDGen, we used urate from UKB as a sensitivity analysis. As mentioned before, we applied the split-sample method for urate, SBP, and DBP to ensure non-overlapping samples in each MVMR analysis. We then conducted MVMR analyses using each split sample, followed by a meta-analysis using a fixed-effect model to obtain a single estimate. The conditional F-statistic of each exposure was calculated as the mean conditional F-statistic of the meta-analyzed MR analyses.

**Results**

For all results, effect estimates (beta) are presented as standard deviation (SD) change in continuous outcome per SD unit increase in exposure [95% confidence interval] (OR (odds ratio) for binary outcome).
UVMR

All the UVMR results, with and without Steiger Filtering, are provided in Supplementary Tables (ST) 5, 6, and 7.

Association of genetically predicted urate levels with BP and eGFR

As shown in Figure 1A, genetically predicted higher urate increased SBP and DBP by 0.08 [95% CI: 0.04 to 0.11; p=6.5e-5] and 0.09 [95% CI: 0.05 to 0.14; p=3.5e-5] SD respectively. The evidence of the causal estimate of urate from CKDGen on eGFR was weak [beta=-0.10; 95% CI: -0.22 to 0.02; p=0.12] while the evidence of the causal estimate of urate from UKB on eGFR was stronger [beta=-0.17; 95% CI: -0.24 to -0.09; p=1.6e-5], with an effect size consistent with the less precise CKDGen estimate.

Association of genetically predicted BP with urate and eGFR

As shown in Figure 1B and 1C, genetically predicted higher BP increased urate levels [SBP: beta= 0.13; 95% CI: 0.08 to 0.18; p=2.3e-8; DBP: beta =0.13; 95% CI: 0.08 to 0.18; p=6.5e-8]. However, there is little evidence for the effects of genetically elevated BP on log(eGFR) [SBP: beta=-0.02; 95% CI: -0.08 to 0.04; p=0.50; DBP: beta=-0.06; 95% CI: -0.13 to 0.004; p=0.64].

Association of genetically predicted eGFR levels with urate and BP

Genetically predicted higher log(eGFR) decreased urate levels from both CKDGen [beta=-0.10; 95% CI: -0.17 to -0.04; p=1.0e-3] (Figure 1D) and UKB [beta=-0.11; 95% CI: -0.18 to -0.04; p=1.1e-3] (ST 5). There was little evidence supporting a causal effect of genetically predicted eGFR on SBP [beta = 0.01; 95% CI: -0.02 to 0.05; p=0.51] or DBP [beta = -0.02; 95% CI: -0.05 to 0.02; p=0.37].
Association of genetically predicted urate levels with early-onset, late-onset, and overall hypertension

As demonstrated in Figure 2, genetically increased urate levels led to a higher risk of early-onset, late-onset, and overall hypertension. The IVW analysis revealed that for each SD increase in genetically predicted urate, the risk of early-onset hypertension increased [OR=1.28; 95% CI: 1.07 to 1.53; p=6.1e-3], as did the risk of late-onset hypertension [OR=1.17; 95% CI: 1.10 to 1.26; p=5.4e-6] and overall hypertension [OR=1.22; 95% CI: 1.12 to 1.32; p=2.5e-6] (ST 7).

Sensitivity analyses of UVMR

The genetic instruments used in all UVMR analyses, with their F-statistics and I\textsuperscript{GX2} statistics, are shown in ST 2 and 4 respectively. All instruments had F-statistics larger than 10 indicating that they are likely strong instruments. All I\textsuperscript{GX2} were larger than 98.64% indicating that the NOME assumption is unlikely to have been violated. However, in all UVMR except urate on gout, Cochran’s Q was much higher than its degrees of freedom, indicating the presence of heterogeneity (see ST 3).

The results of pleiotropy tests of UVMR without Steiger filtering are shown in ST 4. There was directional pleiotropy in the analysis of urate on early-onset hypertension [intercept=0.016; p=2.2e-3]. There was negligible directional pleiotropy in the analysis of urate from CKDGen on SBP [intercept=0.003; p=1.4e-3] and DBP [intercept=0.005; p=4.1e-5], urate from UKB on eGFR [intercept=-0.004; p=6.7e-3], SBP on urate from CKDGen [intercept=0.003; p=4.0e-3], urate on late-onset hypertension [intercept=0.005; p=1.0e-2] and overall hypertension [intercept=0.008; p=1.0e-3]. There was limited evidence of directional pleiotropy for the rest of the main analyses. The weighted median results indicated a similar signal from the pleiotropy tests with evidence of pleiotropy affecting the causal estimate of urate on early-onset hypertension [OR=1.13; 95% CI:
0.91 to 1.40; p=0.26]. Other weighted median results showed consistent evidence with the IVW results, consistent with the negligible pleiotropy effect found using MR-Egger, with the exception of urate (CKDGen) on eGFR [weighted median: beta=-0.06; 95% CI: -0.10 to -0.02; p=5e-3]. All positive control MR results are shown in Supplementary Materials and Figure S2.

Although Steiger filtering removed between 0 and 52 SNPs in the bidirectional UVMR analyses, the causal estimates from IVW remained consistent with the results of the main analyses.

**Sensitivity analyses for eGFR GWAS**

The results of bidirectional UVMR between eGFR (CKDGen2016) and BP were consistent with the main analyses involving eGFR (CKDGen2019) and BP, indicating weak evidence of causal effects between eGFR (CKDGen2016) and BP (see Supplementary Materials).

**MVMR: Independent association of genetically predicted urate and BP levels with eGFR**

The conditional F-statistics of instruments of each exposure were greater than 10, indicating the genetic instruments in MVMR were strong (ST 8). The MVMR provided evidence that increased urate has a causal effect on decreased eGFR, independent of SBP (Figure 3A), and DBP (Figure 3B). Changes in SD log(eGFR) per SD increase in genetically predicted urate were -0.10 [adjusted with SBP; 95% CI: -0.18 to -0.02; p = 1.2e-2] and -0.12 [adjusted with DBP; 95% CI: -0.20 to -0.04; p=4.1e-3]. There was little evidence of a causal effect of genetically predicted higher SBP or DBP on eGFR, independent of urate [SBP: beta = -0.03; 95% CI: -0.13 to 0.07; p=0.58; DBP: beta=-0.09; 95% CI: -0.19 to 0.01; p=6.8e-2]. All these independent causal estimates were consistent with the MVMR results using the split-sample method (Figure S3).
Discussion

We examined the causal relationships between urate, BP, and eGFR by conducting pairwise UVMR and MVMR of urate and BP on eGFR. The UVMR results indicated strong evidence of bidirectional causal effects between urate and BP (both SBP and DBP) and between urate and eGFR. There was also evidence of causal effects of urate on early-onset, late-onset, and overall hypertension, but we could not distinguish whether urate has a larger effect on early-onset hypertension. However, we find inconclusive evidence of causal effects between BP and eGFR. MVMR results indicated that the causal effects of urate on eGFR were independent of BP.

Previously, a bidirectional MR found strong evidence of the causal effect of higher eGFR on lower SBP and DBP, but not vice versa.\(^{47}\) This study used eGFR and blood urea nitrogen (BUN) summary statistics to select genetic instruments for eGFR. Given that higher eGFR results in lower BUN, they assumed eGFR instruments relevant to kidney function, for example, with a positive association with eGFR, should correspondingly have a negative association with BUN. They concluded that better eGFR is causal to lower BP. However, our study does not support the evidence of a causal effect of eGFR on BP. This could be due to the differences in the instrument selection approach or because the BP GWAS used in the previous study was additionally adjusted for body mass index,\(^{48}\) while we conducted our BP GWAS only adjusting for genotyping chip, sex, and age in UKB. Numerous epidemiological studies have reported that evaluated blood pressure is a risk factor for both the onset and progression of CKD\(^{49}\)\(^{53}\) and CKD can also arise as a complication of untreated high blood pressure. Several pathophysiologic mechanisms between BP and kidney function have also been studied 1) from high blood pressure to reduced eGFR, such as endothelial injury\(^{54}\) 2) from reduced eGFR to high blood pressure, such as increased activity of the renin-angiotensin-aldosterone system and sodium dysregulation.\(^{13}\)\(^{55}\) Conducting Two-sample MR requires the underlying assumption of a linear relationship between exposure and outcome.
Renal autoregulatory mechanisms can protect the kidney from the influence of systemic BP and maintain the glomerular hydrostatic pressures. As the majority of UKB participants were relatively healthy, renal autoregulation may attenuate the effects of BP on eGFR observed in MR. Due to concerns about the reliability of non-linear MR, we did not apply non-linear MR to the analyses between BP and eGFR. The weak evidence of causal effects of eGFR on BP may result from biased estimates due to eGFR overestimation compared to measured mGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

A previous MR study, using 26 SNPs identified from a cohort of 110,347 individuals of European ancestry by the Global Urate Genetics Consortium, found limited evidence of a causal relationship between urate and either eGFR or the risk of developing CKD. Another MR study using a genetic urate score indicated hyperuricemia could predict the risk of gout but did not demonstrate predictive power for the development of hypertension or CKD. However, these results could reflect the limited number of genetic instruments and outcome sample size used in these studies. Our MR results with larger sample sizes of both urate and other traits showed consistent results with one previous MR study that found serum urate had a causal effect on increased SBP. Additionally, we identified a bidirectional causal relationship, indicating that elevated BP also leads to increased urate levels.

Assessing the causal role of urate on kidney function in epidemiological studies is challenging due to the inherent relationship between urate and the kidneys. Urate is primarily excreted by the kidneys, and if kidney function is compromised, there is compensatory but insufficient elimination by the gut. Rat experiments have revealed that elevated urate levels impact the proliferation and oxidative stress in vascular smooth muscle cells through the activation of the renin-angiotensin system, and cause endothelial dysfunction, which contributes to the development of glomerular and systemic hypertension. However, in cases of renal disease, the importance of these
mechanisms from experimental studies might be diminished, as systemic hypertension often occurs due to sodium and water retention. This leads to the failure to predict CKD progression using urate. Our study provides further insight by using UVMR with and without Steiger filtering and MVMR, which allows us to estimate the effect of urate, independent of blood pressure, on eGFR and the effect of blood pressure, independent of urate, on eGFR.

Rat experiments indicate that the relationship of urate with hypertension may change based on renal microvascular damage and interstitial inflammation. Early urate-lowering treatments can reduce BP, but hypertension becomes kidney-dependent and irreversible with the progressing renal arteriolopathy and tubulointerstitial inflammation. Moreover, the correlation between urate levels and hypertension diminishes with increasing age and duration of hypertension, suggesting a potential significance of urate in younger individuals with early-onset hypertension. Thus, we conducted a novel MR analysis of urate on early-onset, late-onset, and overall hypertension. While we observed a causal effect of urate on all hypertension types, including some evidence of a directional pleiotropy effect for early-onset hypertension, the wide confidence interval of the effect of urate on early-onset hypertension precludes distinguishing its effect magnitude from that on late-onset hypertension. This is likely due to the sample size as there were only 6,934 cases in the early-onset hypertension GWAS.

Our study had several strengths. Firstly, we harnessed the power of large sample sizes from UKB and CKDGen, which increased the instrument strength in both UVMR and MVMR and decreased the probability of violation of the MR relevance assumption. Secondly, we proactively addressed sample overlap issues in UVMR and MVMR analyses caused by the fact that both urate and eGFR GWAS were taken from CKDGen. We addressed this by using the GWAS conducted with the full UKB sample and the split-sample method in the UVMR and MVMR sensitivity analyses respectively. Both indicated limited evidence of bias caused by the sample overlap. Thirdly, we con-
ducted all bidirectional MR analyses with Steiger filtering to mitigate potential reverse causality concerns between urate, BP, and eGFR. Lastly, we validated the robustness of our findings through a comprehensive set of MR sensitivity analyses, including approaches robust to pleiotropic effects, such as the weighted median and weighted mode methods in UVMR.

Consideration of limitations is essential when interpreting our results. Although sensitivity analyses have shown that most of the pleiotropy effects in our MR analyses are likely to be balanced, the heterogeneity tests indicate a potential violation of the horizontal pleiotropy assumption. Furthermore, despite a relatively large sample from UKB, the cases of early-onset hypertension were limited because the median age at recruitment in UKB is 58 (minimum: 37; maximum: 73). Thus, the power of our MR analysis of urate on early-onset hypertension was limited, resulting in a wide confidence interval. Finally, we only used European-summary-level data in our analyses, which may limit the generalizability of our findings to other ancestries.

In conclusion, we found bidirectional causal effects between urate and both BP and eGFR in the general population. The effects of urate on eGFR were independent of BP. Our findings suggest for the general population, controlling serum urate levels might help to reduce BP and maintain kidney function. Implementing lifestyle modifications or treatment aimed at reducing urate serves as a pragmatic and effective strategy for improving cardiovascular and renal health on a population scale.

References


62. Yang Q, Köttgen A, Dehghan A, et al. Multiple genetic loci influence serum urate levels and


Disclosure

TRG receives funding from Biogen and GSK for unrelated research.

Data Statement

The summary-level data from CKDGen are publicly available [http://ckdgen.imbi.uni-freiburg.de/](http://ckdgen.imbi.uni-freiburg.de/) and OpenGWAS [https://gwas.mrcieu.ac.uk/](https://gwas.mrcieu.ac.uk/). The UK Biobank individual-level data can be accessed through an application [https://www.ukbiobank.ac.uk/](https://www.ukbiobank.ac.uk/).
Acknowledgments

The authors thank the CKDGen consortium (https://ckdgen.imbi.uni-freiburg.de) for publicly sharing the summary-level data. This research has been conducted using the UK Biobank Resource under Application No. 15825. This work was supported by the UK Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/4 and MC_UU_00032/03).

Author Contributions

HT conducted the analyses and drafted the manuscript. VMW and TRG equally contributed to the supervision and manuscript review. All authors approved the final version for submission.
<table>
<thead>
<tr>
<th>Analysis</th>
<th>Exposure</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Univariable MR</strong></td>
<td>Urate (CKDGen)</td>
<td>eGFR (CKDGen2019)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SBP (UKB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DBP (UKB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypertension (UKB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Early-onset hypertension (UKB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Late-onset hypertension (UKB)</td>
</tr>
<tr>
<td></td>
<td>Urate (UKB)</td>
<td>eGFR (CKDGen2019)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gout</td>
</tr>
<tr>
<td></td>
<td>SBP (UKB)</td>
<td>eGFR (CKDGen2019)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>eGFR (CKDGen2016)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urate (CKDGen)</td>
</tr>
<tr>
<td></td>
<td>DBP (UKB)</td>
<td>eGFR (CKDGen2019)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>eGFR (CKDGen2016)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urate (CKDGen)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stroke</td>
</tr>
<tr>
<td></td>
<td>eGFR (CKDGen2019)</td>
<td>Urate (CKDGen)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urate (UKB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SBP (UKB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DBP (UKB)</td>
</tr>
<tr>
<td></td>
<td>eGFR (CKDGen2016)</td>
<td>SBP (UKB)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DBP (UKB)</td>
</tr>
<tr>
<td><strong>Multivariable MR</strong></td>
<td>Urate (CKDGen) + SBP (UKB)</td>
<td>eGFR (CKDGen2019)</td>
</tr>
<tr>
<td></td>
<td>Urate (CKDGen) + DBP (UKB)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urate (UKB Meta) + SBP (UKB Meta)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urate (UKB Meta) + DBP (UKB Meta)</td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Details of all MR analyses conducted in this study. Each trait was presented as the trait name (its corresponding source). We denote urate data from CKDGen as "Urate (CKDGen)" and from UKB as "Urate (UKB)", and distinguish two eGFR GWAS from CKDGen as "eGFR (CKDGen2019)" and "eGFR (CKDGen2016)". To avoid sample overlap between Urate and eGFR, Urate UKB GWAS was used in UVMR while the split-sample method, where the UKB sample was randomly divided into two to conduct GWAS, was used in MVMR. Meta indicated that causal estimates were meta-analyzed from the causal effects of the two subsets. UVMR, univariable Mendelian Randomization; MVMR, multivariable MR; UKB, UK Biobank; SBP and DBP, systolic and diastolic blood pressure; eGFR, estimated glomerular filtration rate; CKDGen, the Chronic Kidney Disease Genetics Consortium.
<table>
<thead>
<tr>
<th>Sources</th>
<th>Trait name</th>
<th>Sample size (% cases, if applicable)</th>
<th>Subgroup</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UKB</strong></td>
<td>Urate</td>
<td>440,466</td>
<td>Full sample</td>
</tr>
<tr>
<td></td>
<td></td>
<td>220,082</td>
<td>Sample 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>220,081</td>
<td>Sample 2</td>
</tr>
<tr>
<td></td>
<td>SBP</td>
<td>432,099</td>
<td>Full sample</td>
</tr>
<tr>
<td></td>
<td></td>
<td>205,299</td>
<td>Sample 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>205,512</td>
<td>Sample 2</td>
</tr>
<tr>
<td></td>
<td>DBP</td>
<td>432,253</td>
<td>Full sample</td>
</tr>
<tr>
<td></td>
<td></td>
<td>205,238</td>
<td>Sample 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>205,512</td>
<td>Sample 2</td>
</tr>
<tr>
<td></td>
<td>Hypertension</td>
<td>462,826 (28.9%)</td>
<td>Full sample</td>
</tr>
<tr>
<td></td>
<td>Early-onset hypertension</td>
<td>336,080 (2.1%)</td>
<td>Full sample</td>
</tr>
<tr>
<td></td>
<td>Late-onset hypertension</td>
<td>424,729 (22.5%)</td>
<td>Full sample</td>
</tr>
<tr>
<td><strong>CKDGen</strong></td>
<td>Urate</td>
<td>288,649</td>
<td>Full sample</td>
</tr>
<tr>
<td></td>
<td>log(eGFR) (CKDGen2019)</td>
<td>567,460</td>
<td>Full sample</td>
</tr>
<tr>
<td></td>
<td>log(eGFR) (CKDGen2016)</td>
<td>133,814</td>
<td>Full sample</td>
</tr>
<tr>
<td><strong>GUGC</strong></td>
<td>Gout</td>
<td>69,374 (3.0%)</td>
<td>Full sample</td>
</tr>
<tr>
<td><strong>MEGASTROKE</strong></td>
<td>Stroke</td>
<td>446,696 (9.1%)</td>
<td>Full sample</td>
</tr>
</tbody>
</table>

Table 2: Details of all genome-wide association studies (GWAS) used in our study. All UKB GWAS were newly conducted; "Full sample" indicates that all participants were used; "Sample 1" and "Sample 2" indicate that the split-sample method was used (see details in Methods and materials). UKB, UK Biobank; SBP and DBP, systolic and diastolic blood pressure; CKDGen, the Chronic Kidney Disease Genetics Consortium; eGFR, estimated glomerular filtration rate; GUGC, Global Urate Genetics Consortium.
Figure 1: Forest plot of the pairwise bidirectional univariable MR results. Each trait is presented as the trait name (its corresponding source). Estimates of the causal effects of the following exposures: A) urate (CKDGen); B) SBP (UKB); C) DBP (UKB); D) eGFR (CKDGen2019), are presented as SD unit change in outcome per SD unit increase in exposure (eGFR is in the SD unit of log(eGFR)). CI, confidence interval; SBP and DBP, systolic and diastolic blood pressure; eGFR, estimated glomerular filtration rate; MR, Mendelian Randomization.

---

**A)** Urate (CKDGen)

- **Outcome**: SBP (UKB)
- **Approach**: Inverse variance weighted
- **Number of SNPs**: 95
- **Beta**: 0.077, 0.029, 0.114
- **95% CI**: 0.000, 0.012
- **Weighted median**: 0.008
- **Weighted mode**: 0.015
- **MR Egger**: -0.011
- **Simple mode**: 0.051

**B)** Urate (CKDGen)

- **Outcome**: eGFR (CKDGen2019)
- **Approach**: Inverse variance weighted
- **Number of SNPs**: 229
- **Beta**: 0.074, 0.017, 0.021
- **95% CI**: 0.000, 0.002
- **Weighted median**: 0.004
- **Weighted mode**: -0.005
- **MR Egger**: -0.001
- **Simple mode**: 0.051

**C)** DBP (UKB)

- **Outcome**: SBP (UKB)
- **Approach**: Inverse variance weighted
- **Number of SNPs**: 237
- **Beta**: -0.043, 0.017, 0.021
- **95% CI**: 0.000, 0.001
- **Weighted median**: -0.054
- **Weighted mode**: -0.054
- **MR Egger**: -0.059
- **Simple mode**: -0.076

**D)** eGFR (CKDGen2019)

- **Outcome**: SBP (UKB)
- **Approach**: Inverse variance weighted
- **Number of SNPs**: 231
- **Beta**: -0.052, -0.015, -0.005
- **95% CI**: 0.000, 0.001
- **Weighted median**: -0.054
- **Weighted mode**: -0.054
- **MR Egger**: -0.059
- **Simple mode**: -0.069

- **Outcome**: DBP (UKB)
- **Approach**: Inverse variance weighted
- **Number of SNPs**: 197
- **Beta**: -0.012, -0.017, -0.017
- **95% CI**: 0.000, 0.000
- **Weighted median**: 0.012
- **Weighted mode**: 0.000
- **MR Egger**: -0.012
- **Simple mode**: -0.214

- **Outcome**: eGFR (CKDGen2019)
- **Approach**: Inverse variance weighted
- **Number of SNPs**: 197
- **Beta**: -0.017, -0.004, -0.005
- **95% CI**: 0.000, 0.000
- **Weighted median**: -0.004
- **Weighted mode**: 0.002
- **MR Egger**: -0.019
- **Simple mode**: 0.006
<table>
<thead>
<tr>
<th>Exposure</th>
<th>Outcome</th>
<th>Approach</th>
<th>Number of SNPs</th>
<th>OR (with 95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urate (CKDGen)</td>
<td>Hypertension (UKB)</td>
<td>Inverse variance weighted</td>
<td>95</td>
<td>1.216 (1.121, 1.319)</td>
<td>0.000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weighted median</td>
<td></td>
<td>1.058 (1.008, 1.116)</td>
<td>0.040</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weighted mode</td>
<td></td>
<td>1.061 (1.013, 1.110)</td>
<td>0.013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MR Egger</td>
<td></td>
<td>0.999 (0.871, 1.146)</td>
<td>0.992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Simple mode</td>
<td></td>
<td>1.088 (0.936, 1.247)</td>
<td>0.058</td>
</tr>
<tr>
<td>Early−onset hypertension (UKB)</td>
<td>Inverse variance weighted</td>
<td>95</td>
<td>1.281 (1.075, 1.528)</td>
<td>0.006</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weighted median</td>
<td></td>
<td>1.130 (0.914, 1.397)</td>
<td>0.250</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weighted mode</td>
<td></td>
<td>1.015 (0.824, 1.250)</td>
<td>0.892</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MR Egger</td>
<td></td>
<td>-0.860 (0.637, 1.160)</td>
<td>0.326</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Simple mode</td>
<td></td>
<td>1.374 (0.876, 2.156)</td>
<td>0.170</td>
</tr>
<tr>
<td>Late−onset hypertension (UKB)</td>
<td>Inverse variance weighted</td>
<td>95</td>
<td>1.173 (1.028, 1.327)</td>
<td>0.050</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weighted median</td>
<td></td>
<td>1.074 (1.013, 1.140)</td>
<td>0.017</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Weighted mode</td>
<td></td>
<td>1.060 (1.003, 1.121)</td>
<td>0.041</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MR Egger</td>
<td></td>
<td>1.029 (0.914, 1.159)</td>
<td>0.640</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Simple mode</td>
<td></td>
<td>1.109 (1.002, 1.226)</td>
<td>0.048</td>
</tr>
</tbody>
</table>

Figure 2: Forest plot of MR results of urate on each type of hypertension. Exposure and outcomes are presented as the trait name (its source name). Estimates of causal effects are presented as OR of each hypertension outcome per SD unit increase in urate (CKDGen). MR, Mendelian randomization; CI, confidence interval. OR, odds ratio.
<table>
<thead>
<tr>
<th>Exposure</th>
<th>Outcome</th>
<th>Approach</th>
<th>Number of SNPs</th>
<th>Beta</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urate (CKDGen)</td>
<td>eGFR (CKDGen2019)</td>
<td>Inverse variance weighted MVMR</td>
<td>96</td>
<td>-0.099</td>
<td>-0.222, 0.024</td>
<td>0.116</td>
</tr>
<tr>
<td>SBP (UKB)</td>
<td></td>
<td>Inverse variance weighted MVMR</td>
<td>65</td>
<td>-0.021</td>
<td>-0.082, 0.040</td>
<td>0.498</td>
</tr>
</tbody>
</table>

Beta (with 95% CI) for SD−unit of log(eGFR) per SD unit increase in exposure

<table>
<thead>
<tr>
<th>Exposure</th>
<th>Outcome</th>
<th>Approach</th>
<th>Number of SNPs</th>
<th>Beta</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urate (CKDGen)</td>
<td>eGFR (CKDGen2019)</td>
<td>Inverse variance weighted MVMR</td>
<td>237</td>
<td>-0.228</td>
<td>-0.129, 0.072</td>
<td>0.578</td>
</tr>
<tr>
<td>DBP (UKB)</td>
<td></td>
<td>Inverse variance weighted MVMR</td>
<td>187</td>
<td>-0.028</td>
<td>-0.181, -0.022</td>
<td>0.012</td>
</tr>
</tbody>
</table>

Figure 3: Forest plot of MVMR of urate and BP on eGFR. Each trait is presented as the trait name (its corresponding source). Estimates of causal effects of the two sets of following exposures: A) urate (CKDGen) and SBP (UKB); B) urate (CKDGen) and DBP (UKB), are presented as SD unit change in log(eGFR) per SD unit increase in exposure. CI, confidence interval; SBP and DBP, systolic and diastolic blood pressure; eGFR, glomerular filtration rate estimated from serum creatinine; MVMR, multivariable MR.